CN105307656B - 巨噬细胞刺激1受体mst1r的喹啉抑制剂 - Google Patents

巨噬细胞刺激1受体mst1r的喹啉抑制剂 Download PDF

Info

Publication number
CN105307656B
CN105307656B CN201480031454.3A CN201480031454A CN105307656B CN 105307656 B CN105307656 B CN 105307656B CN 201480031454 A CN201480031454 A CN 201480031454A CN 105307656 B CN105307656 B CN 105307656B
Authority
CN
China
Prior art keywords
cancer
base
ethyl
quinoline
oxygroup
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480031454.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN105307656A (zh
Inventor
O.沙特
C.埃斯达尔
C.舒尔茨-法登雷希特
J.艾克霍夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lead Discovery Center Co ltd
Original Assignee
Lead Discovery Center Co ltd
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lead Discovery Center Co ltd, Merck Patent GmbH filed Critical Lead Discovery Center Co ltd
Publication of CN105307656A publication Critical patent/CN105307656A/zh
Application granted granted Critical
Publication of CN105307656B publication Critical patent/CN105307656B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480031454.3A 2013-06-06 2014-05-07 巨噬细胞刺激1受体mst1r的喹啉抑制剂 Expired - Fee Related CN105307656B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13002926.7 2013-06-06
EP13002926 2013-06-06
PCT/EP2014/001231 WO2014194975A1 (en) 2013-06-06 2014-05-07 A quinoline inhibitor of the macrophage stimulating 1 receptor mst1 r

Publications (2)

Publication Number Publication Date
CN105307656A CN105307656A (zh) 2016-02-03
CN105307656B true CN105307656B (zh) 2019-02-19

Family

ID=48576706

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480031454.3A Expired - Fee Related CN105307656B (zh) 2013-06-06 2014-05-07 巨噬细胞刺激1受体mst1r的喹啉抑制剂

Country Status (11)

Country Link
US (1) US9481668B2 (enExample)
EP (1) EP3003315B1 (enExample)
JP (1) JP6464395B2 (enExample)
CN (1) CN105307656B (enExample)
AU (1) AU2014277262B2 (enExample)
CA (1) CA2914500C (enExample)
DK (1) DK3003315T3 (enExample)
ES (1) ES2663393T3 (enExample)
IL (1) IL242915B (enExample)
NO (1) NO3003315T3 (enExample)
WO (1) WO2014194975A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021030358A1 (en) 2019-08-12 2021-02-18 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (mst1r) variants and uses thereof
TWI812301B (zh) * 2021-06-24 2023-08-11 南韓商Ｌｇ化學股份有限公司 作為ｒｏｎ抑制劑之新穎尿素衍生物化合物
TW202315628A (zh) * 2021-06-24 2023-04-16 南韓商Ｌｇ化學股份有限公司 作為ｒｏｎ抑制劑之新穎吡啶衍生物化合物
JP2025500917A (ja) 2021-12-16 2025-01-15 キネート バイオファーマ インク． Ｍｅｔキナーゼの阻害剤
WO2025101652A1 (en) * 2023-11-07 2025-05-15 The Scripps Research Institute Selective mammalian sterile 20-like kinase 1 (mst1) modulator compounds as therapeutics for diabetes and liver regeneration
KR102921178B1 (ko) * 2023-11-16 2026-02-02 (주)신테카바이오 헤테로아릴 유도체 화합물 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101248059A (zh) * 2005-04-27 2008-08-20 安姆根有限公司 作为蛋白激酶抑制剂的取代的酰胺衍生物
CN101528702A (zh) * 2006-06-08 2009-09-09 阿雷生物药品公司 喹啉化合物和使用方法
EP2423208A1 (en) * 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101248059A (zh) * 2005-04-27 2008-08-20 安姆根有限公司 作为蛋白激酶抑制剂的取代的酰胺衍生物
CN101528702A (zh) * 2006-06-08 2009-09-09 阿雷生物药品公司 喹啉化合物和使用方法
EP2423208A1 (en) * 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Discovery of a Potent, Selective, and Orally Bioavailable c-Met Inhibitor: 1-(2-Hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458);Longbin Liu等;《Journal of Medicinal Chemistry》;20080614;第51卷(第13期);第3688–3691页 *
Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates;Ted L. Underiner等;《Anti-Cancer Agents in Medicinal Chemistry》;20091231;第10卷(第1期);第7-27页 *
Identification of a novel series of potent RON receptor tyrosine kinase inhibitors;Stéphane Raeppel等;《Bioorganic & Medicinal Chemistry Letters》;20100319;第20卷;第2745-2749页 *

Also Published As

Publication number Publication date
AU2014277262A1 (en) 2016-01-21
CA2914500A1 (en) 2014-12-11
AU2014277262B2 (en) 2019-10-03
CA2914500C (en) 2021-04-20
NO3003315T3 (enExample) 2018-06-16
JP2016520627A (ja) 2016-07-14
WO2014194975A1 (en) 2014-12-11
ES2663393T3 (es) 2018-04-12
EP3003315B1 (en) 2018-01-17
EP3003315A1 (en) 2016-04-13
US20160115154A1 (en) 2016-04-28
US9481668B2 (en) 2016-11-01
IL242915B (en) 2020-04-30
JP6464395B2 (ja) 2019-02-06
DK3003315T3 (en) 2018-04-16
CN105307656A (zh) 2016-02-03

Similar Documents

Publication Publication Date Title
CN102414211B (zh) 3-([1,2,3]三唑-4-基)吡咯并[2,3-b]吡啶衍生物
JP5767205B2 (ja) オートタキシン阻害剤としての複素環式化合物
JP5816182B2 (ja) 腫瘍治療用のスルホキシド誘導体
JP5891234B2 (ja) １ｈ−ピロロ［２，３−ｂ］ピリジン誘導体
JP2011529456A (ja) イミダゾチアジアゾール誘導体
JP6096797B2 (ja) ３−シアノアリール−１Ｈ−ピラゾロ［２．３−ｂ］ピリジン誘導体
JP2013536807A (ja) Ｌｐａ受容体アンタゴニストとしてのピラゾロピリジノン誘導体
EP1866302A1 (de) Pyrazolderivate
JP2014518885A (ja) チアゾール誘導体
JP6464395B2 (ja) マクロファージを刺激する１受容体ｍｓｔｒ１のキノリン阻害剤
CN103403005A (zh) 5-([1,2,3]-三唑-4-基)-7H-吡咯并[2,3-d]嘧啶衍生物
US9283225B2 (en) Pyrido-pyrimidine derivatives
CN104736543A (zh) 用于治疗肿瘤的7-氮杂吲哚-2,7-二氮杂萘衍生物
AU2005304066B2 (en) N,N'-diphenyl urea derivatives suitable as kinase inhibitors
CN102264729B (zh) 6-(1-甲基-1h-吡唑-4-基)-2-{3-[5-(2-吗啉-4-基-乙氧基)-嘧啶-2-基]-苄基}-2h-哒嗪-3-酮磷酸二氢盐的多晶型物及其制备方法
AU2005231907A1 (en) Imidazol derivatives as tyrosine kinase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20181221

Address after: Borussia Dortmund

Applicant after: Lead Discovery Center Co.,Ltd.

Address before: Darmstadt

Applicant before: Merck Patent GmbH

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190219

CF01 Termination of patent right due to non-payment of annual fee